AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01021813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose-matched Placebo to Suvorexant
Description: Oral tablet, administered daily before bedtime
Study NCT03522701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBTI
Description: Refer to the arm description
Study NCT03522701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI
Description: Refer to the arm description
Study NCT03716518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonifying Spleen and Kidney Sequential Regimen
Description: TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
Study NCT03716518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
Description: Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
Study NCT02992158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral activation
Study NCT02992158 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: treatment-as-usual
Description: psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
Study NCT03900754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal administration of oxytocin
Study NCT03900754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02219633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 39652 cream
Description: Applied for 21 days
Study NCT02219633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 39652 cream
Description: Applied for 21 days
Study NCT03160105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DTG + FTC
Description: Switch from standard cART to DTG + FTC dual maintenance therapy.
Study NCT03160105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered monitoring
Description: Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
Study NCT04394455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy
Description: 9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
Study NCT04394455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crisis intervention therapy
Description: 3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
Study NCT04352595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay808
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
Study NCT04352595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay808
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
Study NCT02077387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHild Inhibitory Control (CHIC) Play
Description: CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
Study NCT02077387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
Study NCT01648452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF-releasing implant
Description: 20 ng/day released into the eye
Study NCT04109872 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
Study NCT03963934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention
Description: Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
Study NCT02698813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cells and hyaluronic acid
Study NCT02698813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Study NCT01845428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pravastatin
Description: After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
Study NCT00807937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Study NCT00807937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Study NCT00807937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Study NCT02449863 — intervention group
Intervention type: OTHER
Intervention: Lung ultrasound
Description: Lung ultrasound performed to newborns with respiratory distress
Study NCT01865149 — intervention group
Intervention type: PROCEDURE
Intervention: retrobulbar ultrasound
Description: both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
Study NCT01542593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR
Description: During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery).
Study NCT04042129 — intervention group
Intervention type: OTHER
Intervention: gynecologic operations with urological complications
Study NCT02502708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod
Description: Indoximod will be administered orally twice daily.
Study NCT02502708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered on days 1-5 of every 28 day cycle.
Study NCT02502708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal Radiation
Description: Conformal radiation will be administered on days 3-7 of induction cycle.
Study NCT02502708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered orally daily.
Study NCT02502708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered orally daily.
Study NCT02708108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
Study NCT02708108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity and Exercise Intervention
Description: Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy.
Study NCT03588715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha 2b (peg-IFN-α2b)
Description: Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
Study NCT03588715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117 + 10-1074
Description: Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
Study NCT03100513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: (lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
Study NCT03100513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: PEG as single dose of (3sachets if patient \<75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
Study NCT01323231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XY-Zone
Description: The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i).
Study NCT04380467 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Description: (aviticol) 5x 20,000unit capsules administered monthly over 20 weeks
Study NCT01296334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine LO
Description: intravenous infusion, 10 mg, once, 4 hours
Study NCT01296334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Hi
Description: intravenous infusion, 20 mg, once, 4 hours
Study NCT01296334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine LO
Description: intravenous infusion, 0.3 mg, once, 4 hours
Study NCT01296334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Hi
Description: intravenous infusion, 0.6 mg, once, 4 hours
Study NCT01296334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intravenous infusion, 0.9% saline, once, 4 hours
Study NCT03278379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
Study NCT03014947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11022
Description: Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
Study NCT03014947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira
Description: Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
Study NCT03014947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Humira
Description: Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
Study NCT04294329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided Quadratus lumborum block.
Description: Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
Study NCT04294329 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: US-guided Quadratus lumborum block.
Description: Performance of quadratus lumborum block using ultrasound machine to relieve pain after bariatric surgery
Study NCT04294329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine
Study NCT04294329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: normal saline
Study NCT00974831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Drink Mixture
Description: 22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
Study NCT00974831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose drink
Description: 22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
Study NCT02118675 — intervention group
Intervention type: OTHER
Intervention: Body Measurements
Description: A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
Study NCT02118675 — intervention group
Intervention type: OTHER
Intervention: Body Composition and Circumference measurements
Description: This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
Study NCT02118675 — intervention group
Intervention type: OTHER
Intervention: Whole Body DXA scan
Description: This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
Study NCT02118675 — intervention group
Intervention type: OTHER
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
Study NCT02118675 — intervention group
Intervention type: OTHER
Intervention: BodPod
Description: This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
Study NCT02118675 — intervention group
Intervention type: OTHER
Intervention: Circumferences
Description: This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
Study NCT02927340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Study NCT01552824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CYSTO
Description: Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
Study NCT01552824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vesico-amniotic shunt
Description: In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
Study NCT03630484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Rib Cage Compression
Description: Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
Study NCT03630484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression + Ventilator Hyperinflation
Description: Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
Study NCT04212858 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: zinc-finger protein 217 gene
Description: search for zinc-finger protein 217 gene in myeloma patients
Study NCT01714817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-188667
Study NCT01714817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT01714817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Study NCT01714817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01714817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT01714817 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-188667
Study NCT03440853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASCCI
Description: TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
Study NCT03440853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Technology Delivered Health Education Intervention
Description: The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
Study NCT00443235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan/Prednisone/Velcade
Description: One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)
Study NCT00443235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide/Prednisone/Velcade
Description: One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)
Study NCT03134313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
Study NCT04026854 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of live at work
Description: The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
Study NCT01887587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Study NCT01887587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT01887587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT01887587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone